GENFIT Reports First Quarter 2026 Financial Information and Provides a Corporate Update
GENFIT : Assemblée Générale Mixte du 15 juin 2026 — modalités de mise à disposition des documents préparatoires
GENFIT Annual Combined General Meeting of June 15, 2026 — Availability of Preparatory Documents
GENFIT Annual Combined General Meeting of June 15, 2026 — Availability of Preparatory Documents
GENFIT: Publication of the 2026 Extra-Financial Report (fiscal year 2025)
GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update
GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF
GENFIT to receive US$20M milestone after Ipsen's Iqirvo® exceeds the US$200M threshold in its first full year of net sales
GENFIT Announces 2026 Financial Calendar
GENFIT : GNS561 montre une activité antitumorale prometteuse en combinaison thérapeutique
GENFIT: GNS561 Shows Promising Antitumor Activity in Combination Therapy
GENFIT Announces Appointment of new Chief Medical Officer
GENFIT Reports Third Quarter 2025 Financial Information and Provides a Corporate Update
GENFIT announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market
GENFIT Enters Research Collaboration with EVerZom to Advance Exosome-based Regenerative Technology in ACLF
GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment of ACLF at The Liver Meeting® 2025
GENFIT announces intention to voluntarily delist American Depositary Shares from The Nasdaq Global Select Market
GENFIT Announces Advances Across its ACLF Pipeline at AASLD The Liver Meeting® 2025
GENFIT Reports First-Half 2025 Financial Results and Provides Corporate Update
Wall Street Week Ahead
GENFIT Announces Discontinuation of its VS-01 Program in ACLF: VS-01 Development Refocused on UCD
Genfit assumed with a Buy at H.C. Wainwright
Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
GENFIT: June 17, 2025 Combined Shareholders Meeting Results
GENFIT Reports First Quarter 2025 Financial Information
GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen's Iqirvo® in Italy
GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)
GENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Preparatory Documents
GENFIT to Present Latest ACLF Research at EASL Congress 2025
GENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-F
GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025
GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update
GENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holders
Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEs
GENFIT Announces Revenues and Cash Position as of December 31, 2024
GENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs holders and the Convening of the 2025 OCEANEs holders' general meeting
GENFIT Announces the Amendment of the Final Terms of the Dual Proposal to the 2025 OCEANEs Holders
GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025
GENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan
GENFIT Announces 2025 Financial Calendar
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024
GENFIT Reports Third Quarter 2024 Financial Information
Top 4 Health Care Stocks That May Keep You Up At Night
GENFIT: Ipsen's Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval
GENFIT: Positive Opinion from EMA Committee for Ipsen's Iqirvo® (elafibranor) in Primary Biliary Cholangitis
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH
GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen's Iqirvo® for Primary Biliary Cholangitis